#BEGIN_DRUGCARD DB01627

# AHFS_Codes:
Not Available

# ATC_Codes:
J01FF02

# Absorption:
Rapidly absorbed from the gastrointestinal tract following oral administration. Approximately 20 to 30% absorbed orally in fasting state; absorption decreased when taken with food.

# Biotransformation:
Presumed hepatic, however metabolites have not been fully characterized.

# Brand_Mixtures:
Not Available

# Brand_Names:
Lincocin
Lincocine
Lincolcina
Lincolnensin
Lincomix
Lincomix 20
Lincorex
Mycivin
Pura Ject 100

# CAS_Registry_Number:
154-21-2

# ChEBI_ID:
6472

# Chemical_Formula:
C18H34N2O6S

# Chemical_IUPAC_Name:
(4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide

# Chemical_Structure:
Not Available

# Creation_Date:
2007-08-29 15:12:56 -0600

# DPD_Drug_ID_Number:
30732

# Description:
An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections. [PubChem]

# Dosage_Forms:
Solution	Intravenous

# Drug_Category:
Anti-Bacterial Agents
Lincomycins
Protein Synthesis Inhibitors

# Drug_Interactions:
Aluminium	The aluminium salt decreases the absorption of lincosamides
Atracurium	The agent increases the effect of muscle relaxant
Attapulgite	The aluminium salt decreases the absorption of lincosamides
Doxacurium chloride	The agent increases the effect of muscle relaxant
Erythromycin	Possible antagonism of action with this combination.
Kaolin	The aluminium salt decreases the absorption of lincosamides
Metocurine	The agent increases the effect of muscle relaxant
Mivacurium	The agent increases the effect of muscle relaxant
Pancuronium	The agent increases the effect of muscle relaxant
Pipecuronium	The agent increases the effect of muscle relaxant
Rocuronium	The agent increases the effect of muscle relaxant
Succinylcholine	The agent increases the effect of muscle relaxant
Tubocurarine	The agent increases the effect of muscle relaxant
Vecuronium	The agent increases the effect of muscle relaxant

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.56

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Take on an empty stomach, food decreases absorption.

# GenBank_ID:
Not Available

# Generic_Name:
Lincomycin

# HET_ID:
Not Available

# Half_Life:
The biological half-life after intramuscular or intravenous administration is 5.4 Â± 1.0 hours. The serum half-life of lincomycin may be prolonged in patients with severe impairment of renal function compared to patients with normal renal function. In patients with abnormal hepatic function, serum half-life may be twofold longer than in patients with normal hepatic function.

# InChI_Identifier:
InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11?,12-,13+,14-,15-,16-,18-/m1/s1

# InChI_Key:
InChIKey=OJMMVQQUTAEWLP-ISVUEQNNSA-N

# Indication:
Lincomycin is an antibiotic used in the treatment of staphylococcal, streptococcal, and <i>Bacteroides fragilis</i> infections.

# KEGG_Compound_ID:
C06812

# KEGG_Drug_ID:
D00223

# LIMS_Drug_ID:
1627

# Mechanism_Of_Action:
Lincomycin inhibits protein synthesis in susceptible bacteria by binding to the 50 S subunits of bacterial ribosomes and preventing peptide bond formation upon transcription. It is usually considered bacteriostatic, but may be bactericidal in high concentrations or when used against highly susceptible organisms.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
406.537

# Molecular_Weight_Mono:
406.21375752

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164749212

# Pharmacology:
Lincomycin is a lincosamide antibiotic that comes from the yeast <i>Streptomyces lincolnensis</i>. Lincomycin has been shown to be active in vitro against the following microorganisms: Aerobic gram-positive cocci: <i>Streptococcus pyogenes</i> and <i>Viridans group streptococci</i>; Aerobic gram-positive bacilli: <i>Corynebacterium diphtheriae</i>; Anaerobic gram-positive non-sporeforming bacilli: <i>Propionibacterium acnes</i>; Anaerobic gram-positive sporeforming bacilli: <i>Clostridium tetani</i> and <i>Clostridium perfringens</i>.

# Predicted_LogP_Hydrophobicity:
0.5

# Predicted_LogS:
-1.1

# Predicted_Water_Solubility:
2.93e+01 g/l

# Primary_Accession_No:
DB01627

# Protein_Binding:
Protein binding decreases with increased plasma concentrations. Range, 28 to 86% (average, 70 to 75%). Albumin is not thought to be the primary binding component.

# PubChem_Compound_ID:
656509

# PubChem_Substance_ID:
46506668

# RxList_Link:
http://www.rxlist.com/cgi/generic/lincocin.htm

# Salts:
Lincomycin hydrochloride

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@]1(O[C@]([H])([C@H](NC(=O)C2C[C@@H](CCC)CN2C)[C@@H](C)O)[C@H](O)[C@H](O)[C@H]1O)SC

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
LCM
Lincomycine
Lincomyocin

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:20 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Lincomycin

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10856379	Champney WS, Tober CL: Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol. 2000 Aug;41(2):126-35.
1527036	Odom OW, Hardesty B: Use of 50 S-binding antibiotics to characterize the ribosomal site to which peptidyl-tRNA is bound. J Biol Chem. 1992 Sep 25;267(27):19117-22.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AE005674

# Drug_Target_1_GenBank_ID_Protein:
24054563

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
rplJ

# Drug_Target_1_Gene_Sequence:
>498 bp
ATGGCTTTAAATCTTCAAGACAAACAAGCGATTGTTGCTGAAGTCAGCGAAGTAGCCAAA
GGCGCGCTGTCTGCAGTAGTTGCGGATTCCCGTGGCGTAACTGTAGATAAAATGACTGAA
CTGCGTAAAGCAGGTCGCGAAGCTGGCGTATACATGCGTGTTGTTCGTAACACCCTGCTG
CGCCGTGCTGTTGAAGGTACTCCGTTCGAGTGCCTGAAAGACGCGTTTGTTGGTCCGACC
CTGATTGCATACTCTATGGAACACCCGGGCGCTGCTGCTCGTCTGTTCAAAGAGTTCGCG
AAAGCGAATGCAAAATTTGAGGTCAAAGCCGCTGCCTTTGAAGGTGAGCTGATCCCGGCG
TCTCAGATCGACCGCCTGGCAACTCTGCCGACCTACGAAGAAGCAATTGCACGCCTGATG
GCAACCATGAAAGAAGCTTCGGCTGGCAAACTGGTTCGTACTCTGGCTGCTGTACGCGAT
GCGAAAGAAGCTGCTTAA

# Drug_Target_1_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_1_General_References:
12384590	Jin Q, Yuan Z, Xu J, Wang Y, Shen Y, Lu W, Wang J, Liu H, Yang J, Yang F, Zhang X, Zhang J, Yang G, Wu H, Qu D, Dong J, Sun L, Xue Y, Zhao A, Gao Y, Zhu J, Kan B, Ding K, Chen S, Cheng H, Yao Z, He B, Chen R, Ma D, Qiang B, Wen Y, Hou Y, Yu J: Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res. 2002 Oct 15;30(20):4432-41.
12704152	Wei J, Goldberg MB, Burland V, Venkatesan MM, Deng W, Fournier G, Mayhew GF, Plunkett G 3rd, Rose DJ, Darling A, Mau B, Perna NT, Payne SM, Runyen-Janecky LJ, Zhou S, Schwartz DC, Blattner FR: Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun. 2003 May;71(5):2775-86.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
818

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
17581

# Drug_Target_1_Name:
50S ribosomal protein L10

# Drug_Target_1_Number_of_Residues:
164

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00466	Ribosomal_L10

# Drug_Target_1_Protein_Sequence:
>50S ribosomal protein L10
ALNLQDKQAIVAEVSEVAKGALSAVVADSRGVTVDKMTELRKAGREAGVYMRVVRNTLLR
RAVEGTPFECLKDAFVGPTLIAYSMEHPGAAARLFKEFAKANAKFEVKAAAFEGELIPAS
QIDRLATLPTYEEAIARLMATMKEASAGKLVRTLAAVRDAKEAA

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Protein L10 is also a translational repressor protein. It controls the translation of the rplJL-rpoBC operon by binding to its mRNA

# Drug_Target_1_SwissProt_ID:
P0A7J6

# Drug_Target_1_SwissProt_Name:
RL10_SHIFL

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
9.51

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01627
